12 assets in Transplant Rejection

Therapeutic assets addressing Transplant Rejection, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Busulfanum Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cyclophosphamide Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Fludarabine Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Plerixafor Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Sirolimus Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Tacrolimus Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Ruxolitinib Transplant Rejection	Arkansas Children's Hospital Research Institute	P1/2	CC (45)
Daratumumab Transplant Rejection	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Early P1	C (39)
Hyaluronidase Fihj Transplant Rejection	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Early P1	C (39)
dnp007 Transplant Rejection	Seoul National University Hospital	P1	NR ()